Cabinet approves establishment of national medical tourism council to boost healthcare sector    Egypt's investment authority GAFI hosts forum with China to link business, innovation leaders    CBE governor meets Beijing delegation to discuss economic, financial cooperation    Egypt's Gypto Pharma, US Dawa Pharmaceuticals sign strategic alliance    Egypt to unveil 'national economic development narrative' in June, focused on key economic targets    Egypt's Foreign Minister calls new Somali counterpart, reaffirms support    Italy's consumer, business confidence decline in April '25    "5,000 Years of Civilizational Dialogue" theme for Korea-Egypt 30th anniversary event    Egypt's Al-Sisi, Angola's Lourenço discuss ties, African security in Cairo talks    Two new recycling projects launched in Egypt with EGP 1.7bn investment    Egypt's ambassador to Palestine congratulates Al-Sheikh on new senior state role    Egypt's TMG eyes $17bn sales from potential major Iraq project    Egypt's Health Min. discusses childhood cancer initiative with WHO    Egypt pleads before ICJ over Israel's obligations in occupied Palestine    Asia-Pacific stocks rise on Wall Street cues    Egypt's EDA discusses local pharmaceutical manufacturing with Bayer    Sudan conflict, bilateral ties dominate talks between Al-Sisi, Al-Burhan in Cairo    Egypt expresses condolences to Canada over Vancouver incident    Cairo's Madinaty and Katameya Dunes Golf Courses set to host 2025 Pan Arab Golf Championship from May 7-10    Egypt's Health Min. strengthens healthcare ties with Bayer    Egypt's Ministry of Health launches trachoma elimination campaign in 7 governorates    EHA explores strategic partnership with Türkiye's Modest Group    Between Women Filmmakers' Caravan opens 5th round of Film Consultancy Programme for Arab filmmakers    Fourth Cairo Photo Week set for May, expanding across 14 Downtown locations    Egypt's PM follows up on Julius Nyerere dam project in Tanzania    Ancient military commander's tomb unearthed in Ismailia    Egypt's FM inspects Julius Nyerere Dam project in Tanzania    Egypt's FM praises ties with Tanzania    Egypt to host global celebration for Grand Egyptian Museum opening on July 3    Ancient Egyptian royal tomb unearthed in Sohag    Egypt hosts World Aquatics Open Water Swimming World Cup in Somabay for 3rd consecutive year    Egyptian Minister praises Nile Basin consultations, voices GERD concerns    49th Hassan II Trophy and 28th Lalla Meryem Cup Officially Launched in Morocco    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Paris Olympics opening draws record viewers    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



HIV drugs may get new role in fighting cancer
A drug previously tested to treat HIV proves efficient in cancer patients, prompting a new hope for millions of sufferers
Reuters Published in Ahram Online on 27 - 10 - 2013

A type of HIV medicine that stops the AIDS virus from entering immune system cells could in future be put to work against cancer in new combination therapies being developed by drug companies.
Interest in using so-called CCR5 inhibitors to fight tumors was fuelled last year when U.S. researchers, testing the drugs on mice, reported a marked reduction in aggressive breast cancer cells spreading to the animals' lungs.
Researchers from the Thomas Jefferson University Kimmel Cancer Center described the results as "dramatic" after they were published in the Journal of Cancer Research.
Now industry analysts at Citi believe Merck & Co Inc is set to take things to the next stage by testing its CCR5 drug vicriviroc in cancer patients. The product was abandoned as a treatment for HIV in 2010 following an unsuccessful study.
Pfizer Inc and Bristol-Myers Squibb - which also have similar drugs in their portfolios - could follow suit, Citi said in a note on Friday.
Asked to comment on the suggestion that it would start testing vicriviroc in patients in 2014 as part of a combination therapy for cancer, a spokesman for Merck said: "We have not disclosed any such plans."
Citi said it expected vicriviroc to re-enter clinical testing in combination with cancer immunotherapy as Merck explores its potential across multiple tumor types, including melanoma, colorectal, breast, prostate and liver cancer.
Immunotherapy, which harnesses the body's immune system to fight cancer, is a hot new area for cancer research, with some experts predicting the approach will in future form the backbone of many cancer treatments.
However, drug combinations are expected to be critical to its success as oncologists will need to block cancer cells on several fronts at once.
One option is to combine two immunotherapies, while another approach, also being pursued by other companies like Roche Holding AG and AstraZeneca Plc, is to combine immunotherapy medicines with different drug types.
CCR5 inhibitors are one such option, given the encouraging signals from pre-clinical research. As these drugs have already been studied in HIV, their development could be relatively rapid.
Pfizer could also start clinical trials in cancer with its approved CCR5 drug Selzentry, which is currently marketed for HIV via the ViiV Healthcare alliance with GlaxoSmithKline Plc and Shionogi & Co Ltd.
Bristol, meanwhile, has a dual CCR2/5 inhibitor in mid-stage Phase II development, which is being tested for diabetes and kidney disease.
http://english.ahram.org.eg/News/84852.aspx

Clic here to read the story from its source.